The global liver disease diagnostics market size was valued at USD 35.37 billion in 2022 and is anticipated to grow at a CAGR of 6.5% from 2023 to 2030. One of the key factors anticipated to propel the market for liver disease diagnostics is the increasing number of acute and chronic liver illnesses. Factors such as rising efforts made by major players to create highly sensitive and quick tests to identify liver diseases in specific populations, like pregnant women and HIV-positive patients, increasing research and development of precise diagnostic systems that enhance timely diagnosis and outcomes for patients, the introduction of novel ways to diagnose diseases, and changing behaviors, such as increased alcohol consumption and bad diets, are anticipated to have a favorable effect on the market for liver disease diagnostics.
Rising prevalence of acute and chronic liver diseases is one of the major factors expected to drive the market for liver disease diagnostics. For instance, according to the WHO, in 2020, an estimated 830,000 people died due to liver cancer. Additionally, according to a research report named "Global Epidemiology of Chronic Liver Disease" which was released in June 2021, chronic liver disease (CLD), which affects about 1.5 billion people worldwide, is one of the major causes of mortality and morbidity.
Rising initiatives undertaken by key players to develop highly sensitive and rapid tests to detect liver diseases in specific populations such as pregnant women and HIV-positive patients is anticipated to boost the market for liver disease diagnostics. For instance, In January 2020, Siemens introduced the enhanced liver fibrosis (ELF) diagnostic service in the United States. The ELF test combines the quantitative measurements taken in the serum sample with three direct indicators of liver fibrosis to provide a straightforward, unit-less numeric score using an algorithm.
Furthermore, increasing R&D of accurate diagnostic systems to improve early diagnosis and patient outcomes is expected to propel the growth of the market for liver disease diagnostics. In March 2020, F. Hoffmann-La Roche Ltd. was granted Breakthrough Device Designation for Elecsys GALAD score. Elecsys GALAD score was developed under the Roche Diagnostics Liver Indication Program to improve diagnostic workflow and support clinicians by providing accurate information.
The presence of favorable reimbursement policies by Medicare, Medicaid, and other health insurance programs is expected to accelerate the market for liver disease diagnostics. The Medicare coverage policy in CodeMap, a leading source of reimbursement solutions, and Medicare compliance includes the piccolo express liver panel plus developed by Abbott with a medicare reimbursement of USD 30.89.
In addition, the introduction of novel methods to diagnose diseases is likely to have a positive impact on the market for liver disease diagnostics. For instance, FibroScan GO, a cheap and cost-effective instrument for assessing liver health, was introduced by Echosens in the UK in March 2022.
Changing behavior of the population, such as increased alcohol consumption and bad diets is another key factor anticipated to affect the market for liver disease diagnostics.For instance, a temporary increase in alcohol consumption during the COVID-19 pandemic can significantly increase long-term ALD-related mortality and morbidity, and it was observed that alcohol consumption increases by up to 25% in the U.S., as per a research study published in December 2021 and titled "Effect of Increased Alcohol Consumption During the COVID-19 Pandemic on Alcohol-Associated Liver Disease: A Modelling Study ".
Additionally, according to the same source, this rise in consumption may lead to 8,000 additional fatalities from alcohol-associated liver diseases, 18,700 instances of failure of the liver, and 1,000 incidents of liver cancer by 2040. As a result, there will likely be a greater need for efficient and cutting-edge diagnostic tools so that patients can receive proper medical care.
The imaging segment accounted for the largest revenue share and is expected to grow at the fastest CAGR. This is attributed to the rising number of initiatives taken by key players in the liver disease diagnostics market to develop advanced imaging techniques. Laboratory tests are carried out using urine, blood, and other fluid samples to diagnose liver function. Whereas, imaging includes ultrasound, X-ray, Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, and others.
In addition, the key players in the market for liver disease diagnostics are undertaking initiatives to support non-profit organizations to raise awareness and help physicians in detecting liver diseases. In January 2020, Echosens supported Fatty Liver Foundation (FLF) by providing FibroScan to help clinicians detect, monitor, and prevent liver diseases.
The hospitals segment held the largest revenue share of around 45% in 2022 as the majority of patients rely on hospitals well-equipped with diagnostic testing devices. Hospitals provide optimal care to patients and enable early detection & diagnosis, thus boosting the growth of the market for liver disease diagnostics. Furthermore, the ongoing development of healthcare infrastructure is anticipated to enhance the existing hospital facilities.
The laboratories segment is expected to grow at the fastest CAGR of 7.0% over the forecast period. Various laboratories and institutes conduct awareness programs to diagnose hepatic organ disease. For instance, in December 2017, the Institute of Liver and Biliary Sciences collaborated with Mylan Laboratories to conduct screening and awareness programs. The aim was to provide quality screening and testing facilities for more than 1,000 patients in Delhi. The program conducted tests such as Hepatitis B & C, Fibroscan, and ALT.
North America dominated the market and accounted for the largest revenue share of over 40% in 2022 followed by Europe. High investments in R&D and the presence of key players are some factors expected to be responsible for the growth of the market for liver disease diagnostics in the region. Furthermore, the presence of organizations that provide information regarding the diagnosis of diseases to patients is expected to fuel the growth of the market for liver disease diagnostics. One such organization is GetPalliativeCare.org which provides palliative care information related to diagnostic methods such as endoscopy, CT scan, and biopsy.
For instance, non-alcoholic fatty liver disease, which affected over 7 million people in 2020, was the most prevalent liver illness, and liver cancer is the fastest-rising and most lethal form of cancer in Canada, according to the 2021 report of the Canadian Liver Foundation. As a result, the region's demand for goods for the early diagnosis of liver illness is anticipated to be high, which will drive expansion in the North American market under study.
Asia Pacific is expected to grow at the fastest CAGR of 8.6% during the forecast period. Increasing geriatric population and awareness about regular check-ups are contributing to the growth of the market for liver disease diagnostics in this region. Furthermore, regulatory approval of advanced technologies that can be integrated with imaging systems is estimated to drive regional growth. For instance, in August 2018, Liver Multi Scan received clearance from the Therapeutic Goods Administration (TGA) to diagnose patients with highly prevalent diseases in Australia such as NAFLD and NASH.
The key players are implementing multiple strategies for the development of innovative technologies to advance patient care. In August 2019, Boston Scientific Corporation acquired BTG plc to offer access to advanced technologies for better patient care. In June 2022, Echosens and Novo Nordisk worked together to implement non-invasive diagnostic procedures for non-alcoholic steatohepatitis (NASH) and raise awareness of the condition and the value of early detection and treatment. The companies want to quadruple the number of diagnosis for people suffering from moderate to severe NASH by 2025.
Market size value in 2023
USD 37.68 billion
Revenue forecast in 2030
USD 58.62 billion
CAGR of 6.5% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Diagnosis technique, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
Abbott; F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Randox Laboratories Ltd.; Boston Scientific Corporation; Laboratory Corporation of America Holdings; Fujifilm Corporation; Horiba Medical; Siemens Healthcare GmbH
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global liver disease diagnostics market based on diagnosis technique, end-use, and region:
Diagnosis Technique Outlook (Revenue, USD Million, 2018 - 2030)
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East and Africa
b. The global liver disease diagnostics market size was estimated at USD 35.37 billion in 2022 and is expected to reach USD 37.68 billion in 2023.
b. The global liver disease diagnostics market is expected to grow at a compound annual growth rate of 6.5% from 2023 to 2030 to reach USD 58.62 billion by 2030.
b. Imaging dominated the liver disease diagnostics market with a share of 29.68% in 2022. This is attributable to the presence of techniques such as ultrasound, X-ray, Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, and others.
b. Some key players operating in the liver disease diagnostics market include Abbott, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Randox Laboratories Ltd., Boston Scientific Corporation, Laboratory Corporation of America Holdings, Fujifilm Corporation, Horiba Medical, and Siemens Healthcare GmbH.
b. Key factors that are driving the liver disease diagnostics market growth include the rising prevalence of acute & chronic liver disease and increasing R&D of accurate diagnostic systems to improve early diagnosis and patient outcomes.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."